Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term. Read why MEDP stock is a Strong Buy.

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

IQVIA Holdings Inc. IQV will release its fourth-quarter 2024 results on Feb. 6, before market open. See Zacks Earnings ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Fortune Media and Korn Media began this annual ranking 27 years ago…and many familiar names dominate the “most-admired-companies” list. A lot goes into ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX – Research Report), Amgen (AMGN – ...

Let's sort the S&P 500 healthcare sector again to show the 10 stocks with the highest percentages of "buy" or equivalent ratings. Only five companies are on both this list and the above growth list: ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Caprock Group LLC decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 9.6% in the fourth quarter ...

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World's Most Admired ...

(HealthDay News) — Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in October ...